Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
48 results about "Metabolite profiling" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Device for quantitative analysis of a drug or metabolite profile
ActiveUS20070003965A1Improve efficiencyImprove reliabilityBioreactor/fermenter combinationsBiological substance pretreatmentsMedicineInternal standard
A device, in particular a sample preparation device for the quantitative analysis of a drug and / or metabolite profile in a biological sample, which includes an insert for such a device being impregnated with at least one internal standard, to the internal standard itself, and to a kit comprising the device. Further, the invention also relates to an apparatus containing the device, and to a method for the quantitative analysis of a drug and / or metabolite profile in a biological sample employing the device.
Owner:BIOCRATES LIFE SCIENCES AG
Apparatus and method for analyzing a metabolite profile
ActiveUS20070004044A1Reduce the amount requiredEasy to analyze resultsParticle spectrometer methodsMass spectrometric analysisMedicineMass Spectrometry-Mass Spectrometry
An apparatus and method analyzes a metabolic profile in a biological sample. The apparatus includes an input unit for inputting the drugs and / or metabolites to be screened; a controlling unit for determining a parameter set for metabolites preparation and for mass spectrometry analysis depending on the input of the kind of metabolites to be screened; a treatment unit for preparing the metabolites to be screened depending on the determined parameter set; a mass spectrometer for performing mass spectrometry analysis on prepared metabolites depending on the parameter set; a database for storing results of analyzing and parameter sets for metabolite preparation and for mass spectrometry analyses; and an evaluation unit for evaluating the results of mass spectrometry by use of reference results stored in the database to output an analysis of the metabolites profile.
Owner:BIOCRATES LIFE SCIENCES AG
Serum specificity metabolite spectrum for patient with lung cancer, and building method thereof
ActiveCN103616450AEasy to handleStrong qualitative analysis abilityComponent separationGas phaseOriginal data
Owner:HUZHOU CENT HOSPITAL
Methods of diagnosing acute cardiac allograft rejection
InactiveUS20110171645A1Acute allograft rejectionMicrobiological testing/measurementIsotope separationCardiac allograftT cell
The present invention relates to methods of diagnosing acute rejection of a cardiac allograft using genomic expression profiling, proteomic expression profiling, metabolite profiling, or alloreactive T-cell genomic expression profiling,
Owner:THE UNIV OF BRITISH COLUMBIA
Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics
The present invention provides methods for optimizing clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. The methods of the present invention may further comprise determining the level of at least one long-chain methotrexate polyglutamate (MTXPG) in a sample obtained from the individual. The present invention also provides methods for generating a pharmacogenetic index for predicting clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. In addition, the present invention provides methods for optimizing therapeutic efficacy of chemotherapy in an individual by calculating the level of at least one long-chain MTXPG in a sample obtained from the individual.
Owner:EXAGEN INC
Methods and uses for metabolic profiling for clostridium difficile infection
ActiveUS20140296134A1Excellent disease classificationBiocideMicrobiological testing/measurementClostridium difficile infectionsMetabolic profile
Embodiments include methods for generating a metabolite profile of a stool sample and methods of assessing the status of a subject using the metabolic profile derived from a stool sample.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST
Biofluid metabolite profiling as a tool for early prediction of autoimmunity and type 1 diabetes risk
The invention concerns a method for diagnosing a child's susceptibility for developing type 1 diabetes by using a serum metabolite as biomarker. The invention concerns also a method for prevention of the onset of type 1 diabetes in a child.
Owner:ZORA BIOSCIENCES OY
Early detection of recurrent breast cancer using metabolite profiling
InactiveUS20130023056A1High degree of sensitivityHigh degree of specificityComponent separationOrganic compound preparationDiseaseDiagnostic test
A monitoring test for recurrent breast cancer with a high degree of sensitivity and specificity is provided that detects the presence of a panel of multiplicity of biomarkers that were identified using metabolite profiling methods. The test is capable of detecting breast cancer recurrence about a years earlier than current available monitoring diagnostic tests. The panel of biomarkers is identified using a combination of nuclear magnetic resonance (NMR) and two dimensional gas chromatography-mass spectrometry (GC×GC-MS) to produce the metabolite profiles of serum samples. The NMR and GC×GC-MS data are analyzed by multivariate statistical methods to compare identified metabolite signals between samples from patients with recurrence of breast cancer and those from patients having no evidence of disease.
Owner:PURDUE RES FOUND INC
Device for quantitative analysis of a drug or metabolite profile
ActiveUS8116983B2Improve efficiencyImprove reliabilityParticle spectrometer methodsMass spectrometric analysisMedicineInternal standard
A device, in particular a sample preparation device for the quantitative analysis of a drug and / or metabolite profile in a biological sample, which includes an insert for such a device being impregnated with at least one internal standard, to the internal standard itself, and to a kit comprising the device. Further, the invention also relates to an apparatus containing the device, and to a method for the quantitative analysis of a drug and / or metabolite profile in a biological sample employing the device.
Owner:BIOCRATES LIFE SCIENCES AG
Metabolic biomarkers for memory loss
ActiveUS10900980B2Peptide/protein ingredientsMicrobiological testing/measurementMemory disorderIncreased risk
Owner:GEORGETOWN UNIV +1
Method for optimizing fermentation medium by improving rapamycin production by using metabolic profiling analysis
InactiveCN103088104AIncrease productionComponent separationMicrobiological testing/measurementPrimary metabolismMetabolic profile
The invention provides a method for optimizing a fermentation medium by improving rapamycin production by using metabolic profiling analysis, which researches dynamic changes and differences of bacteria intracellular metabolites under the culture conditions of initial fermentation medium and optimized fermentation medium by using the methods of dynamic detection and metabolic profiling analysis. The analysis result of partial least squares indicates that the bacteria primary metabolite profile and the rapamycin production have correlation and a further dynamic adding measure is provided to the medium by analyzing the dynamic changes of the key compounds combining related processes. Due to the research of S.hygroscopicus U1-6E7 fermentation medium, the rapamycin production is improved from 196mg / L to 307mg / L and is improved by 56.6%, which indicates that rational guidance of optimization of fermentation mediums by dynamic detection combining the metabolite profile analysis method is capable of successfully improving fermentation level of antibiotic and providing a new idea for optimization of fermentation mediums.
Owner:TIANJIN UNIV
Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics
Owner:CYPRESS BIOSCI +1
Metabonomics testing method for spermine-regulated mammalian intestinal development
InactiveCN103913478AEnhance digestion and absorptionPromote healthy growthAnalysis using nuclear magnetic resonanceAnimal scienceMammal
The invention discloses a metabonomics testing method for spermine-regulated mammalian intestinal development. A novel way is provided for accurately evaluating an overall nutrition metabolism effect for promoting the animal intestinal development through spermine based on the metabonomics technology. Change of an animal intestinal metabolite spectrogram can fully reflect comprehensive influence in aspects such as nutrition, individual and environment and timely and sensitively reflect correlation among animal spermine nutrition and metabolism conditions thereof as well as intestinal development. According to the method, biological markers related to the intestinal spermine nutrition process can be screened, the intrinsic quality of the spermine nutrition process is disclosed, the method has important theory and practice significance for perfecting digestive absorption functions of the animals, optimizing the feed formula and improving healthy growth of the animals, and the gaps that the overall nutrition metabolism conditions of animal intestinal development cannot be evaluated by combining with the metabonomics and the animal intestinal development cannot be improved are filled. Moreover, the research result proves that the method has actual application values in breeding industry.
Owner:SICHUAN AGRI UNIV
Manipulation of flavonoid biosynthetic pathway
InactiveUS20120204289A1Increased PAIncrease nutritionMicrobiological testing/measurementLibrary screeningProanthocyanidinFlavonoid biosynthesis
The present invention relates to a method of identifying a gene encoding a polypeptide or polypeptide isoform which is substantially more active in either a proanthocyanidin (PA) or anthocyanin (ANT) pathway of a plant, said method including providing material from said plant; and an oligonucleotide probe capable of hybridizing with RNA from a gene encoding a polypeptide which is active in a flavonoid biosynthetic pathway; extracting RNA from said plant material; hybridizing the oligonucleotide probe with the RNA to generate an expression profile; measuring PA and / or ANT levels in said plant material to generate a metabolic profile; comparing said expression profile with said metabolite profile to identify said gene encoding a polypeptide or polypeptide isoform which is substantially active in either a PA or ANT pathway.
Owner:AGRI VICTORIA SERVICES PTY LTD
Metabolic Biomarkers for Memory Loss
The present invention relates to methods of determining if a subject has an increased risk of suffering from memory impairment. The methods comprise analyzing at least one plasma sample from the subject to determine a value of the subject's metabolite profile and comparing the value of the subject's metabolite profile with the value of a normal metabolite profile. A change in the value of the subject's metabolite profile, over normal values is indicative that the subject has an increased risk of suffering from memory impairment compared to a normal individual.
Owner:GEORGETOWN UNIV +1
Detection method for o-dihydroxy metabolite spectrum in urine
The invention provides a method for testing a spectrum of o-dihydroxy metabolites in urine. Solid-phase extraction is carried out by using phenylo boric acid so as to purify and enrich the o-dihydroxy metabolites; and liquid chromatography-mass spectrometry is adopted to test a characteristic spectrum of the o-dihydroxy metabolites. Concentration by centrifuging is carried out by collecting formic acid-methanol water eluate; and residua are dissolved in water and analyzed after centrifugation. The invention provides a new method for testing the spectrum of the o-dihydroxy metabolites and lays a foundation for further discovering new diagnostic markers of breast cancer.
Owner:ZHEJIANG UNIV
Metabolites for oral health and uses thereof
The present invention provides various methods of using metabolite profiles correlated with periodontal disease or a health oral status for the diagnosis of periodontal disease, identification of responders and, or non-responders to therapeutic agents for periodontal disease, a method to test the efficacy of test compounds to prevent periodontal disease. The present invention also provides for a dentifrice composition containing an effective amount of a metabolite therapeutic agent which brings about a greater change in metabolite levels compared to a control dentifrice composition.
Owner:COLGATE PALMOLIVE CO
Amino acid metabolomics-based method for researching anti-insomnia action mechanism of sugemule
ActiveCN110999860AOptimizing Assay ConditionsCompounds screening/testingNervous disorderTryptamineNeurotransmitter systems
The invention relates to an amino acid metabolomics-based method for researching an anti-insomnia action mechanism of sugemule. Amino acid metabolome in each of tissues of the brains of para-chlorophenylalanine (PCPA) insomnic model rats before and after gavage with the sugemule is analyzed by applying a gas chromatography-mass spectrometer (GC-MS) method; endogenous compounds are identified by astandard fingerprint bank; changes of metabolite maps of all parts of the brains are analyzed and related metabolic markers are assayed by employing principal component analysis (PCA) and partial least squares-discrimination analysis (PLS-DA) modes; a targeting metabolomics research is conducted by applying liquid chromatograph-mass spectrometer (LC-MS) to explore content changes of neurotransmitters including 5-hydroxytryptamine, gamma-aminobutyric acid (GABA), glutamic acid (Glu) and the like in the brain tissues and related metabolites; by seeking for difference metabolites related with thecurative effect of the sugemule and metabolic pathways of the difference metabolites from brain tissue samples of clinical rats, the anti-insomnia action mechanism and an action site of the sugemuleare specified; and a metabolomics research means is applied for the first time by the amino acid metabolomics-based method to preliminarily confirm the action mechanism of the sugemule regulating andcontrolling a sleep-wake rhythm by a neurotransmitter system.
Owner:田继兰
Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics
The present invention provides methods for optimizing clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. The methods of the present invention may further comprise determining the level of at least one long-chain methotrexate polyglutamate (MTXPG) in a sample obtained from the individual. The present invention also provides methods for generating a pharmacogenetic index for predicting clinical responsiveness to chemotherapy in an individual through genotypic analysis of polymorphisms in at least one gene. In addition, the present invention provides methods for optimizing therapeutic efficacy of chemotherapy in an individual by calculating the level of at least one long-chain MTXPG in a sample obtained from the individual.
Owner:PROMETHEUS LAB
Systems and methods for metabolite topography of the brain with magnetic resonance imaging
Metabolite profiles are generated from magnetic resonance images. These metabolite profiles indicate a topography of the metabolites in one or more anatomical regions. The magnetic resonance images can be metabolite images, such as those obtained using hyperpolarized 13C-MRI. The metabolite profiles can be generated by parcellating the magnetic resonance images into different regions, computing z-scores for those regions, and generating the metabolite profile based on the computed z-scores.
Owner:SUNNYBROOK RES INST
Fermentation process
Owner:LANZATECH NZ INC
MR system and method for detecting metabolites
InactiveCN104662433AAccurate detectionLow background signal contaminationMeasurements using NMR spectroscopyDiagnostic recording/measuringNutationResonance
Owner:KONINKLJIJKE PHILIPS NV
Methods for optimizing clinical responsiveness to methotrexate therapy using metabolite profiling and pharmacogenetics
Owner:PROMETHEUS LAB
Methods and compositions for regulating production of proanthocyanidins
ActiveUS20120278914A1Altered flavonoidRegulates flavonoid synthesisImmunoglobulinsFermentationBiotechnologySecondary metabolite
The invention provides methods and compositions for the modulation of proanthocynidin (“PA;” condensed tannin) production in plants. The methods of the invention allow creation of plants having novel phenotypes, such as alterations in levels of PA or in the types of tissues in which PAs are produced. Altered expression of PA in plants may be achieved, for instance without significantly affecting anthocyanin content or overall secondary metabolite profiles. Alternatively, expression of PA in plants may be achieved while also affecting anthocyanin content.
Owner:NOBLE RES INST LLC
Metabolites for oral health and uses thereof
The present invention provides various methods of using metabolite profiles correlated with periodontal disease or a health oral status for the diagnosis of periodontal disease, identification of responders and, or non-responders to therapeutic agents for periodontal disease, a method to test the efficacy of test compounds to prevent periodontal disease. The present invention also provides for a dentifrice composition containing an effective amount of a metabolite therapeutic agent which brings about a greater change in metabolite levels compared to a control dentifrice composition.
Owner:COLGATE PALMOLIVE CO
Obese population-specific biomarker composition and use thereof
Disclosed is a blood plasma specific metabolite profile, in particular a biomarker composition obtained via obese population blood plasma specific metabolite profile screening. Also disclosed are a use of the biomarker composition for obesity risk assessment, diagnosis, early diagnosis and pathological staging, and an obesity risk assessment, diagnosis, early diagnosis and pathological staging method. The biomarker composition of the present invention may be used for the early diagnosis of obesity.
Owner:BGI SHENZHEN CO LTD +1
Device, Method, And System For Identifying Organisms And Determining Their Sensitivity To Toxic Substances Using The Changes In The Concentrations Of Metabolites Present In Growth Medium
Devices, methods and systems are for identifying the cell type of an unknown microorganism. The device includes: an apparatus for culturing unknown organism(s), a diagnostic data acquisition tool and a computer program. The method includes: incubation of the sample with a growth medium (with or without toxins), and an analysis of the metabolites detected in the sample. The computer system compares the results collected from the device to reference metabolite profiles.
Owner:LEWIS IAN
Metabolite detection system and operation thereof
InactiveUS20150253402A1Low background signal contaminationImprove signal-to-noise ratioMagnetic measurementsDiagnostic recording/measuringPulse sequenceQuantum filtering
A magnetic resonance (MR) system for detecting concentrations of one or more metabolites in a volume of interest (VOI), the system including at least one controller which: may apply to the VOI a multiple quantum filter (MQF) Point Resolved Spetroscopy (PRESS) sequence comprising first and second 90° RF pulses, a third 90° RF pulse, first and second 180° adiabatic pulses, and a composite dual-band delay alternating with nutation for tailored excitation (DANTE) pulse train having a plurality of N block pulses (N being an integer), the DANTE pulse train situated in time between the first and second 90° RF pulses, the first and second 180° adiabatic pulses situated in time after third 90° RF pulse; detect MR Free Induced Decay (FID) signal emitted from the VOI; and / or reconstruct the detected MR FID signal to obtain metabolite spectrum information.
Owner:KONINKLJIJKE PHILIPS NV
Metabolic profiling in tissue and serum is indicative of tumor differentiation in prostate cancer
InactiveUS20150310169A1Enhancing risk predictionHealth-index calculationMicrobiological testing/measurementMetabolic profileGleason Score 6
The invention provides methods and products to detect the presence of unidentified high grade prostate tumors in a subject with a Gleason score 7 prostate tumor. The method comprises obtaining a biological sample from a subject in need thereof, measuring a profile of metabolites in the biological sample, wherein the metabolites are differentially expressed in Gleason score 6 versus Gleason score 8 prostate tumors, and classifying the profile of the metabolites to assign a grade to the sample based on the profile of the metabolites.
Owner:DANA FARBER CANCER INST INC +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com